AWARD NUMBER: W81XWH-18-1-0007

TITLE: Development of Novel Molecularly Targeted Therapy to Secreted Frizzled-Related Protein 2 for Breast Cancer

PRINCIPAL INVESTIGATOR: Nancy Demore

CONTRACTING ORGANIZATION: Medical University of South Carolina
Charleston, SC 29425

REPORT DATE: March 2020

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
March 2020	Annual Report	01 March 2019 – 28 February 2020

4. TITLE AND SUBTITLE

Development of Novel Molecularly Targeted Therapy to Secreted Frizzled-Related Protein 2 for Breast Cancer

5a. CONTRACT NUMBER

5b. GRANT NUMBER
W81XWH-18-1-0007

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)
PI: Nancy DeMore
PPI: Ann-Marie Broome

E-Mail: demore@musc.edu

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

MEDICAL UNIVERSITY OF SOUTH
CAROLINA179 ASHLEY
AVECHARLESTON SC 29425-89

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT Most antiangiogenic drugs evaluated in breast cancer clinical trials inhibit angiogenesis by targeting the VEGF pathway. VEGF is a driver of tumor angiogenesis in breast cancer, however modest or negative phase III clinical results suggest further targets, pathways, or factors play a significant role. Furstenburger et al. evaluated VEGF expression in primary breast cancers from patients and adjacent normal breast tissue and found no increase in VEGF levels. We hypothesized that pro-angiogenesis factors other than VEGF are drivers of human breast cancer angiogenesis. To identify these pro-angiogenesis factors, we developed a novel method of immuno-laser capture microdissection coupled with RNA amplification and genome-wide gene expression to profile tumor vasculature cells from human breast tumors with comparison to normal breast samples. In our analysis we identified that secreted frizzle-related protein 2 (SFRP2) mRNA levels were increased more than 6-fold in breast cancer endothelium compared to normal vessels from benign breast tissue, and as shown by immunohistochemistry 85% of breast tumors showed intense staining for SFRP2 in the neovasculature. Importantly, SFRP2 was highly expressed in the vasculature of luminal, Her2/neu, and basal tumors. Interestingly, VEGF was expressed at the same level in both tumor and benign endothelium, suggesting again that VEGF might not be a major driver of breast tumor angiogenesis. We subsequently showed that SFRP2 induces angiogenesis in vitro and in vivo, and that antagonism of SFRP2 with a monoclonal antibody inhibits triple negative breast carcinoma and angiosarcoma growth in mice. We further identified that the angiogenic activity of SFRP2 is mediated by activating the non-canonical Wnt calcineurin/ nuclear factor of activated T-cells c3 (NFATc3) pathway. NFAT is a transcription factor that plays a critical role in mediating angiogenic responses. We have generated a humanized SFRP2 mAb that is nonimmunogenic and efficacious against triple negative breast cancer.

15. SUBJECT TERMS
WNT, breast cancer, metaplastic breast cancer, angiogenesis, NFAT, immunotherapy

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
Unclassified	Unclassified	Unclassified	Unclassified		19b. TELEPHONE NUMBER *(include area code)*

TABLE OF CONTENTS

1. **INTRODUCTION:** The purpose of this research is to establish a novel therapy for metastatic breast cancer and determine its mechanism of action. We have humanized a monoclonal antibody to secreted frizzled related protein 2 (SFRP2) and will determine the pharmacokinetic, pharmacodynamic, efficacy and toxicity profile in breast cancer. We will determine mechanism of action in the Wnt-signaling pathway with molecular imaging *in vivo* and will establish if there is increased efficacy in combination with other therapies.

2. **KEYWORDS:** WNT, breast cancer, metaplastic breast cancer, angiogenesis, NFAT, immunotherapy.

3. **ACCOMPLISHMENTS: What were the major goals of the project?**

Major Task 1: Determine PK, and PD of the hSFRP2 mAb in immunocompetent BALB/CJ mice. (Months 1-6) **This task is 90% complete (DEMORE and BROOME)**

Major Task 2: Determine the efficacy of hSFRP2 mAb in triple negative 4T1 breast cancer cells in BALB/CJ mice, human triple negative cells in nude mice (MDA-MB-231 and HS578t), and a triple negative PDX breast cancer (TM00089) *in vivo*. Will test multiple doses in 4T1 and MDA-MB-231 (2, 4 ,10 and 20 mg/kg) (6-15 months) **This task is 75% completed. (DEMORE and BROOME)**

Major Task 3: Determine the effects of the hSFRP2 mAb on host and tumor immune system in 4T1 cells in BALB/CJ mice. (Months 12-18) **This task is 50% complete (DEMORE)**

Major Task 4: Show that hSFRP2 mAb reduces NFAT-dependent transcriptional activity in 4T1 and HS578t cells *in vivo* using molecular imaging (Months 18-26) **Not started**

Major Task 4: Show whether the hSFRP2 mAb is additive or synergistic with agents that have a a similar mechanism of action: Drugs that inhibit NFAT activation (bevacizumab) and drugs that inhibit PD-1. Show whether the hSFRP2 mAb is additive or synergistic with agents that have a different mechanism of action: SFRP2 has no effect on proliferation(24), we will evaluate for synergy with anti-mitotic drugs. (months 24-36). **This task is 25% complete (DEMORE)**

Major Task 5: Show whether the hSFRP2 mAb is effective in doxorubicin-resistant breast cancer. (Months 24-36) We are in the process of culturing MDA-MB-231 cells with doxorubicin to create a dox-resistant cell line. **This task is 40% complete (DeMore)**

What was accomplished under these goals?

1) Major activities were

a.) Determine the pharmacodynamics of the hSFRP2 mAb in tumor bearing mice and non-tumor b earing mice

b). Identify and characterize an alternate triple negative GEMM cell line (KPB) that grows in immunocompetent mice so that we can evaluate efficacy of hsFRP2 mAb with PD-1 inhibitor.

c). Determine the effect of hSFRP2 mAb on T-cells in vitro

D) Develop a doxorubicin-resistant breast cancer cell line.

2) Specific objectives:

A) Determine the Pharmacodynamics of the hSFRP2 mAb in mice.

B) Determine the efficacy of the hSFRP2 mAb in KPB triple negative breast cancer in vitro and in vivo.

C) Show that the hSFRP2 mAb activates NFATc3 on T-cells, and effects on downstream cytokines

D) Evaluate whether the SFRP2mAb is efficacious in breast cancer cell line resistant to doxorubicin.

3) Significant results. Note: In the section below we also tested the antibody on osteosarcoma GEMM cells. This data is included, although DOD funding was NOT USED for this experiment, and this was done under a separate IACUC protocol.

Major Task 1) Biodistribution of hSFRP2 mAb in vivo. We assessed the uptake and clearance patterns of fluorophore-conjugated SFRP2 (**Fig. 1**) compared to that of fluorophore-conjugated IgG (**Fig. 2**) after tail vein injection into breast cancer model mice and control mice, i.e., naïve mice containing no tumor. We first acquired a longitudinal (in time) series of images at the following time points: just prior to injection of the antibodies (to

obtain a baseline signal with no fluorophore signal); immediately after the injection of the antibodies; and then 24, 48, 72, and 96 hours after the injection of antibodies.

Prior to injecting the fluorophore-tagged antibodies, we imaged the fluorophore-conjugated antibodies in solution in a non-fluorescent vial to quantify the total injected fluorophore and to measure a clean fluorescence spectra. For the analysis of the *in vivo* fluorescence imaging, we first determined the component spectra for the fluorophore-tagged antibodies and for the mouse prior to antibody injection. We used spectral decomposition to decompose each image at each longitudinal time point into its component images and then recorded image-intensity-scaled fluorophore component images for each mouse at each longitudinal time point. As seen **in Fig. 1** (top panels), fluorophore-conjugated SFRP2 accumulated within the orthotopically implanted tumor within 24 hours post injection, with minimal uptake in normal organ of the control mouse. Signal intensity was retained over the 96 hours period. As expected, there was some minor uptake into the liver. Unbound SFRP2 (**Fig. 1** (bottom panels)) was quickly excreted through the urinary bladder over a 72 hours period. In naïve control mice, SFRP2 rapidly cleared through the urinary bladder over a 72 hours period.



Fig. 1. Longitudinal live fluorescent imaging of mice orthotopically implanted with MDA-MB-231 cells (top panels) or without tumors (bottom panels) injected with fluorophore-labeled SFRP2 mAbcover a period of 96 hours. Representative imaging hotmaps analyzed on the same scale of the mice are shown (N=3 for each). In mice with tumor, SFRP2 mAb is taken up in the tumor and liver and unbound mAb is excreted trough the urinary bladder. Mice without tumors do not accumulate SFRP2 mAb and the mAb is excreted out of the

As seen **in Fig. 2** (top panels), in contrast, fluorophore-conjugated IgG accumulated nonspecifically within the whole animal within 24 hours post injection. Signal intensity was retained over the 96 hours period. As expected, the IgG was excreted through the urinary bladder. A similar imaging profile was observed in naïve mice injected with fluorophore-conjugated IgG (**Fig. 2** (bottom panels)).

Upon completion of the longitudinal *in vivo* fluorescence imaging, we injected each mouse a second time with fluorescing antibodies. Seventy-two hours after the second injection, we euthanized the mice and harvested the organs and tumor. We acquired additional fluorescence images of the harvested organs from each mouse. For the analysis of the organ and tumor images, we used the component spectra for the fluorophore-tagged antibodies and determined the component spectra for each organ from a mouse that had not been injected with the fluorophore-tagged antibodies. We used spectral decomposition to decompose each image into its component images and then recorded image-intensity-scaled fluorophore component images for each organ and tumor. Data processing and analysis is currently underway.



Fig. 2. Longitudinal live fluorescent imaging of mice orthotopically implanted with MDA-MB-231 cells (top panels) or without tumors (bottom panels) injected with fluorophore-labeled IgG over a period of 96 hours. Representative imaging hotmaps analyzed on the same scale of the mice are shown (N=3). Fluorescence is observed throughout the whole animal indicating nonspecific binding of igG.

Major Task 2) Determine the efficacy of hSFRP2 mAb in triple negative breast cancer cells: For the MDA-MB-231 experiment there were 27 female nude mice that were injected with 1 million cells in 100 µl composed of 50% HBSS and 50% Matrigel. We stopped the experiment 65 days post-injection of cancer cells when we confirmed the cancer cells were not forming tumors. We confirmed by euthanizing two mice and seeing no cancer cells by pathology in the mammary fat pad. Therefore, we sought to find another triple negative cell line to study.

KPB GEMM triple negative cells: We obtained the KPB GEMM triple negative breast cancer cell line from Dr. Chuck Perou from UNC. We chose this cell line because it grows in immunocompromised mice, so we can use it to study combination therapy with immunotherapy. Also, Dr. Perou's data shows that this cell line is particularly resistant to immunotherapy, therefore if we see synergy with immunotherapy this would be a very significant finding. Our first studies were to characterize whether the KPB cell line has SFRP2, FZD5, and PD-L1 protein. For comparison, we tested against two osteosarcoma GEMM cell lines (RF420 and RF577). Cells were lysed, protein was extracted and subjected to Western blot with antibodies to SFRP2, FZD5, PD-L1, and actin. This shows that the KPB breast cancer cell line expresses PDL-1, SFRP2 and FZD5 (**Fig. 3**)



Fig. 3. Western blot using cell lysates from KPB breast cancer cells, and RF420 and RF577 osteosarcoma cells. KPB has higher protein levels of PD-L1, with RF577 having the lowest level. All three cell types have SFRP2 and FZD5 protein.

Next, we evaluated whether KPB cells are sensitive to the hSFRP2 mAb in vitro. KPB cells were seeded at 15,000 cells / well in 96 well plate and allowed to settle overnight. The next day cells were treated with 10uM

IgG control or 10uM hSFRP2 mAb. After 1 hour of treatment the cells were labeled using reagents from the PromoCell Apoptotic/Necrotic cells detection kit (#PK-CA707-30017), according the manufactures protocol. Images were acquired using the EVOS FLc digital imaging system and counted using ImageJ. N=12 per group. This showed an increase in apoptosis in hSFRP2 mAb treated cells (n=12, IgG= 4.93% ± 0.19%, hsFRP2 (mAb) = 43.54%± 0.16%, p<0.0001, **Fig. 4**)



Fig. 4. hSFRP2 mAb increases apoptosis in vitro in KPB triple negative breast cancer cells *in vitro*. N=12 per group, p<0.0001)

We recently received IACUC and ACURO amendment approval for to evaluate the effect of the hSFRP2 mAb alone and in combination with PD-1 inhibitor which will be performed in Year 3.

Major task 3) Effects of hSFRP2 mAb on Wnt Signaling in T-cells. In our previous progress report, we showed that SFRP2 activated NFAT and CD38 in T cells *in vitro*. We further evaluated the effects of antagonizing sFRP2 on CD38.

hSFRP2 mAb inhibits CD38 in T cells and restores NAD+. Since expression of CD38 was regulated by SFRP2, we evaluated whether hSFRP2 mAb treatment of T-cells *in vitro* inhibits CD38 and also restores NAD+ levels in TGFβ-exposed T-cells. TGFβ is a cytokine present in the tumor microenvironment that increases CD38 from T-cells. Treatment of T-cells with TGFβ resulted in an increase in SFRP2 by Western blot which was reversed with the hSFRP2 mAb (**Fig. 5A**). FACS analysis showed a statistically significant increase in CD38 + cells with the addition of TCR/TGFβ, which was significantly inhibited by the hSFRP2 mAb (**Fig. 5B**, N=3, p<0.001), Along with this there was a decrease in NAD+ concentration with TGFβ, which was increased with hSFRP2 treatment (**Fig. 5C**, N=3, p=0.02). PD-1 s a checkpoint inhibitor known to be regulated by NFAT. We treated T-cells with TGF-β, which resulted in and increase in the number PD-1 positive CD8 and CD4 cells, which was inhibited with the addition of the hsFRP2 mAb (**Fig. 5D, E**).



Fig. 5: Quantification of CD38, PD-1 and NAD+ splenic T-cells in response to treatment with hSFPR2 mAb. A) T cells were treated with IL-2, IL-2 + TCR, IL-2 + TCR/TGFβ, or the combination plus hSFRP2 mAb (10μM). Cell lysates were prepared for western blot and probed for SFPR2. B,C) Mouse splenocytes were treated with IL-2 (6,000 u/well), with or without TCR/TGFβ (5ng/ml) for 3 days, and with or without hSFRP2 mAb (10μM) for 48 hours (n=3 per group). CD4 and CD8+ T-cells were then isolated. B) CD38+ cells were quantified by FACS analysis C) NAD+ levels were measured. D-E) CD8+ T-cells were analyzed by flow cytometry for differential PD-1 expression. * $p < 0.001$, ** $p<0.05$.

Major task 4) While we were working to identify and characterize an alternate murine triple negative cell line that we could use to study synergy with immunotherapy, we evaluated whether there is synergy of the hSFRP2 mAb with immunotherapy in another tumor cell line that we are working on in the lab. This study was conducted under a separate IACUC protocol and not using DOD funds, however we are including this data as it will guide our similar experiments that we will be conducting this year with the KPB triple negative cell line. The purpose of this study was to analyze the efficacy of a humanized SFPR2 mAb against osteosarcoma tumor models as a monotherapy and in combination with PD-1 inhibition and examine the role of SFRP2 in immune signaling. Our *in vivo* experiments utilized immunocompetent C57/BL6 mice injected with osteosarcoma cell line RF577 via tail vein allowing lung metastases to develop for seven days prior to commencement of treatment. Our first experiment was with hSFRP2 mAb as monotherapy on established tumors, with IgG control (4mg/kg iv q3days) or hSFRP2 mAb (4 mg/kg iv q 3 days) started on day 7 and continued for 21 days. Mice were then euthanized, and lungs and spleens were collected. Surface macro metastases were counted. This showed a statistically significant reduction in the number of surface metastases (**Fig. 6A**, $p<0.05$). Splenic T cells and tumor infiltrating lymphocytes were collected and subjected to flow cytometry comparing activation markers CD38, CD103 and CD5 between control and hSFRP2 treated mice, which showed a significant decrease in splenic T-cell and tumor infiltrating lymphocyte CD38, but not CD103 or CD5 (**Fig. 6B**). A portion of lungs were fixed in formalin and embedded in paraffin, and immunohistochemistry with antibody to CD31 was performed to quantify changes in tumor angiogenesis. This showed a reduction in microvascular density in hSFRP2 mAb treated tumors (**Fig. 6C**, $p<0.001$).).



Fig. 6. *In vivo* monotherapy with hSFPR2 mAb in RF420 lung metastasis model. Osteosarcoma RF420 cells were injected intravenously in C57BL6 mice. Treatments with an IgG1 control or hSFRP2 mAb (4 mg/kg every 3 days), starting 10 days after the injection of tumor cells. Three weeks later, the animals were euthanized, their lungs were resected, and surface nodules were counted. A) *Top left* - Quantification of lung metastases in IgG1 treated control mice versus hSFRP2 mAb treated mice. (n=10). *Bottom left* - Representative lungs with tumor metastases. B) T-cells isolated from spleens of mice from in vivo experiment. Cells were stained for immune markers to CD38, CD103, or CD-5 which were labeled with a fluorochrome and mean fluorescent intensity (MFI) was analyzed by FACS. Dot blot graphs showing the measurements of fluorescence obtained from T-cells isolated from 4 different spleens for each treatment (N=4). Only CD38 was statistically different with hSFRP2 mAb in both splenocytes and TILs. C) Tumors from in vivo experiment were removed at necropsy stained with CD31 at a dilution of 1:200. ** p≤0.001.

Next, we evaluated whether the hSFRP2 mAb is synergistic with PD-1 mAb. C57BL6 mice were injected with RF420 cells via tail vein, and treatments started on day 10. Treatments were an IgG1 control (n=12), mouse anti-PD-1 (n=10), hSFRP2 mAb (n=12), and a combination of both anti-PD-1 and hSFRP2 mAb (n=11). Lungs were resected after 21 days of treatment, and serum was collected. Surface metastases were counted in all groups. This showed no effect of the PD-1 mAb as monotherapy on tumor metastases. The hSFRP2 mAb was efficacious as monotherapy at inhibited tumor growth, with an additive effect in combination with the PD-1 mAb (**Fig. 7A**). There were no signs of toxicity with any of the treatment groups, and no weight loss (**Fig. 7B**). Serum was collected and tested for SFRP2 protein by ELISA comparing mice with no tumor and mice with tumor in the IgG group. This showed and elevation in serum SFRP2 in mice with tumor (**Fig. 7C**).



Fig. 7. *In vivo* metastatic osteosarcoma experiment with hSFRP2 mAb and anti-PD-1 mono and combination therapies performed with metastatic osteosarcoma RF420 cells C57/bl6 mice. RF420 cells were injected via tail vein into c57BL6 mice. Treatments were anti-PD-1 (200ug/100ul q3 days) IP (n=10), hSFPR2 (4mg/kg q3 days) IV (n=12), or a combination of both treatments (n=11) compared to IgG1 control (n=11). A) Lungs removed after three weeks of treatment were analyzed for metastatic disease and metastatic nodules were quantified for each treatment group. B) Animal weights were taken starting on the first day of treatment until the final day of treatment on day 19. C) Serum was taken from IgG1 control treated mice immediately following euthanasia tumors analyzed by ELISA for SFPR2 expression and compared with serum from normal C57/BL6 mice with no tumors injected (n=3).

cells were treated with doxorubicin (0.01uM to 10uM). Cells remained in treatment for 7 days. On day 7, cells were stained with Cyquant direct proliferation assay (ThermoFisher #C35011). The plate was read using the BioTek synergy2 plate reader at 480 nm wavelength**.** Using an on-line IC50 calculator, the IC50 was determined to be 0.12 µM. Cells have been serially cultured for 6 months starting in 0.002 µM, and are now in a concentration of .012 µM. An IC50 curve will be repeated, and an in vivo experiment will be performed this year comparing the sensitivity of wild-type MDA-MB-231 cells with dox-resistant MDA-MB-231 cells. As mentioned, we did have a problem with tumor take using the MDA-MB-231 cells previously, however, we have successfully used this cell line in the past and will increase the concentration of Matrigel in the next in vivo experiment, and will inject a larger number of cells.



4). Other achievements

What opportunities for training and professional development has the project provided?

Nothing to report

How were the results disseminated to communities of interest?

- This data was presented as an oral presentation March28,2019 at the Society of Surgical Oncology Annual Meeting in San Diego., and as an oral presentation at the American Pediatric Society September, 2019.
- This data was published: Denise Garcia, Patrick Nasarre, Ingrid V. Bonilla, Eleanor Hilliard, Yuri K. Peterson, Laura Spruill, Anne-Marie Broome, Elizabeth G. Hill, Jason T. Yustein, MD, Shikhar Mehrotra, Nancy Klauber-DeMore, Development of a Novel Humanized Monoclonal Antibody to Secreted Frizzled-Related Protein-2 that Inhibits Triple Negative Breast Cancer and Angiosarcoma Growth in vivo. Annals of Surgical Oncology, 2019 Dec;26(13):4782-4790.: PMID: 31515721

What do you plan to do during the next reporting period to accomplish the goals?

1) Treat mice with KPB triple negative tumor with hSFRP2 mAb as monotherapy, and in combination with PD-1 mAb and anti-angiogenic therapy.

2) Transfect breast cancer cell lines with NFAT luciferase for the in vivo molecular imaging studies.

3. Treat tumors resistant to doxorubicin in vivo with hSFRP2 mAb

4. **IMPACT:** *Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:*

What was the impact on the development of the principal discipline(s) of the project?

What was the impact on other disciplines?

- SFRP2 is expressed in other tumors, including sarcoma. Using non-DOD funds, we have conducted studies in parallel that show that the SFRP2 antibody is also effective in osteosarcoma in combination with immunotherapy. The mechanism and information obtained through the DOD grant will also impact patients with sarcoma.

What was the impact on technology transfer?

- We are using the data generated in this grant to talk with pharmaceutical companies and venture capital to attempt to raise funds for GMP manufacturing, pre-clinical tox studies, and Phase 1 trial. It is our hope that we will be successful at obtaining funds in the next reporting cycle.
- We have filed a patent on combination of hsFRP2 mAb and PD-1 inhbitor (see below)

- **What was the impact on society beyond science and technology?**
  - Nothing to report

5. **CHANGES/PROBLEMS:**

Changes in approach and reasons for change

- We had problems with cell lines initially planned for in this grant, so we moved toward the KPB GEMM triple negative cell line.

Actual or anticipated problems or delays and actions or plans to resolve them

- None

Changes that had a significant impact on expenditures

- Nothing to report

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Significant changes in use or care of human subjects

None

Significant changes in use or care of vertebrate animals.

We added an additional cell line and obtained IACUC and ACURO approval

Significant changes in use of biohazards and/or select agents

None

6. **PRODUCTS:** *List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state "Nothing to Report."*

Publications, conference papers, and presentations

Report only the major publication(s) resulting from the work under this award.

Journal publications. *List peer-reviewed articles or papers appearing in scientific, technical, or professional journals. Identify for each publication: Author(s); title; journal; volume: year; page numbers; status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no)*

- Denise Garcia, Patrick Nasarre, Ingrid V. Bonilla, Eleanor Hilliard, Yuri K. Peterson, Laura Spruill, Ann-Marie Broome, Elizabeth G. Hill, Jason T. Yustein, MD, Shikhar Mehrotra, Nancy Klauber-DeMore, Development of a Novel Humanized Monoclonal Antibody to Secreted Frizzled-Related Protein-2 that Inhibits Triple Negative Breast Cancer and Angiosarcoma Growth in vivo. Annals of Surgical Oncology, 2019 Dec;26(13):4782-4790.: PMID: 31515721 Federal support acknowledged.

Books or other non-periodical, one-time publications. None

Other publications, conference papers, and presentations.

hSFRP2 mab Inhibits tumor growth, Society of Surgical Oncology Annual Meeting, March, 2019, San Diego, CA

Website(s) or other Internet site(s)

None

Technologies or techniques

None

Inventions, patent applications, and/or licenses

PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER United States Patent Application No. 62/737,155 filed September 27, 2018, Inventor Dr. Nancy DeMore

Other Products

None

7. **PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**

What individuals have worked on the project?

Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate "no change."

The individuals who have worked on the grant are unchanged from the original submission. These include: Dr. Nancy DeMore, Dr. Ann-Marie Broome, Dr. Shikhar Merhotra, Dr. Elizabeth Hill, and Dr. Patrick Nasarre

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Dr. DeMore's effort on the DOD grant has not changed. However, she did receive to additional grants

PI DeMore 4/1/19-3/31/20
Sponsor: Hollings Cancer Center Pre-Clinical and Clinical Concept Award
Calendar months 0.36
Total Budget: $2,3605
Overlap: None

Title of Project: Window of Opportunity Trial using Curcumin for Breast Cancer
Goals: To evaluate whether there are changes in tumor proliferation and apoptosis in patients treated with curcumin in a window of opportunity trial
Co-PI DeMore 4/1/19-3/31/20
Sponsor: Hollings Cancer Center Pre-Clinical and Clinical Concept Award
Calendar months 0.36
Total Budget: $50,000
Title of Project: Adoptive Transfer of Tumor Infiltrating Lymphocytes for the Treatment of Breast Cancer
Goals: To obtain preliminary data of successful collection and expansion of human tumor infiltrating lymphocytes from human breast cancer
Overlap: None

What other organizations were involved as partners?

Nothing to report

8. **SPECIAL REPORTING REQUIREMENTS**
   - **COLLABORATIVE AWARDS:** *For collaborative awards, independent reports are required from **BOTH** the Initiating PI and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to https://ers.amedd.army.mil for each unique award.*
   - **QUAD CHARTS:** *If applicable, the Quad Chart (available on https://www.usamraa.army.mil) should be updated and submitted with attachments.*

9. **APPENDICES:** *Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc. Reminder: Pages shall be consecutively numbered throughout the report. **DO NOT RENUMBER PAGES IN THE APPENDICES.***

********** **ADDITIONAL NOTES:**

MARKING OF PROPRIETARY INFORMATION: Data that was developed partially or exclusively at private expense shall be marked as "Proprietary Data" and Distribution Statement B included on the cover page of the report. Federal government approval is required before including Distribution Statement B. The recipient/PI shall coordinate with the COR/GOR to obtain approval. **REPORTS NOT PROPERLY MARKED FOR LIMITATION WILL BE DISTRIBUTED AS APPROVED FOR PUBLIC RELEASE.** It is the responsibility of the Principal Investigator to advise the COR/GOR when restricted limitation assigned to a document can be downgraded to "Approved for Public Release." **DO NOT USE THE WORD "CONFIDENTIAL" WHEN MARKING DOCUMENTS. DO NOT USE WATERMARKS WHEN MARKING DOCUMENTS.**